Abstract
The serum level of procollagen type I carboxyterminal propeptide (P1CP), which has been used as an index of collagen synthesis in patients with various fibrotic diseases during the active stage, was measured using enzyme-linked immunosorbent assay in 61 patients with systemic sclerosis (SSc) and in 21 control subjects. The mean P1CP level in the SSc patients was significantly higher than in the normal controls (mean ± SD, 326 ± 319 vs 128 ± 87 ng/ml; p<0.005). In 36% of the SSc patients, the serum P1CP level was significantly elevated more than two standard deviations above the mean control value. The mean serum P1CP level in patients with diffuse SSc was significantly higher than in those with limited SSc (411 ± 373 vs 255 ± 199 ng/ml; p<0.05). In addition, the SSc patients with elevated serum P1CP levels showed a significantly greater incidence of lung fibrosis and joint involvement than those with normal P1CP levels (p<0.005 and p<0.05, respectively). These results suggest that the serum P1CP level is a useful indicator of the severity of disease in SSc patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
LeRoy EC (1974) Increased collagen synthesis by scleroderma fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 54: 880–889
Uitto J, Bauer E, Eisen A (1979) Scleroderma: increased biosynthesis of triplehelical type I and type III procollagens associated with unaltered expression of collagenase in skin fibroblasts in culture. J Clin Invest 64: 921–930
Fleischmajer R, Perlish JS, Krieg T, Timpl R (1981) Variability in collagen and fibronectin synthesis by scleroderma fibroblasts in primary culture. J Invest Dermatol 76: 400–403
Rohde H, Vargas L, Hahn E, et al (1979) Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest 9: 451–459
Frei A, Zimmerman A, Weigand K (1984) The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. Hepatology 4: 830–834
Risteli L, Risteli J (1990) Non-invasive methods for detection of organ fibrosis. In: Rojkind M (ed) Focus on conective tissue in health and disease, vol 1. CRS Press, Boca Raton, pp 61–98
Krieg T, Langer I, Gerstmeier H, et al (1986) Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma. J Invest Dermatol 87: 788–791
Majewski S, Skiendzielewska A, Makiela B, et al (1987) Serum levels of type III collagen aminopropeptide in patients with systemic scleroderma. Arch Dermatol Res 279: 484–486
Black CM, McWhirter A, Harrison NK, et al (1989) Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. Br J Rheumatol 28: 98–103
Sasaki T, Nakajima H (1989) Prolyl hydroxylase and procollagen III peptide levels in the sera from patients with collagen diseases and psoriasis. J Dermatol 16: 207–211
Herrmann K, Schulze E, Heckmann M, et al (1990) Type III collagen aminopropeptide and laminin P1 levels in serum of patients with silicosis-associated and idiopathic systemic sclerosis. Br J Dermatol 123: 1–7
Heickendorff L, Parvez A, Bjerring P, et al. (1991) Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. Acta Derm Venereol (Stockh) 71: 185–188
Melkko J, Niemi S, Risteli L, Risteli J (1990) Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36: 1328–1332
Kahari VM, Vuorio T, Nanto-Salonen K, et al. (1984) Increased type I collagen mRNA levels in cultured scleroderma fibroblasts. Biochem Bophys Acta 78: 183–186
American Rheumatism Association (1980) Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581–590
LeRoy EC, Black C, Fleishmaje P, et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15: 202–205
Takehara K, Moroi Y, Ishibashi Y (1985) Antinuclear antibodies in the relatives of patients with systemic sclerosis. Br J Dermatol 112: 23–33
Katayama N, Terao T (1992) Relationship of serum levels of pro-type I collagen peptide, pro-type III collagen peptide and type IV 7S collagen with cervical maturation. Gynecol Obstet Invest 34: 24–26
Martin GR, Timpl R, Muller P, Kuhn K (1985) The genetically distinct collagens. Trends Biochem Sci 10: 285–287
Fessler JH, Fessler LI (1978) Biosynthesis of procollagens. Annu Rev Biochem 47: 129–162
Oikarinen A, Autio P, Vuori J, et al (1992) Systemic glucocorticoid treatment decreases serum concentrations of carboxyl propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. Br J Dermatol 126: 172–178
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kikuchi, K., Ihn, H., Sato, S. et al. Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis. Arch Dermatol Res 286, 77–80 (1994). https://doi.org/10.1007/BF00370731
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00370731